X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.
Lead Product(s): Pimozide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: JW-600
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Safety Shot
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Biovanta, an OTC product with low-dose aspirin and other anti-inflammatory ingredients, reduced inflammation when applied to affected cells and tissues, making it the first scientifically proven 100% naturally derived, OTC medicine for treating cough, cold and sore throat.
Lead Product(s): Biovanta
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Biovanta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
Kintor Pharmaceutical's Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Kintor Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
The study on the effects of proxalutamide on COVID-19 has received national IRB approval and will be conducted in Brasilia, Brazil, in non-hospitalized patients with mildto-moderate COVID-19 disease.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corpometria Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
ANDROCOV trial is for a Generic Anti-androgen as a Treatment For COVID-19 taking Dutasteride, Ivermectin, Azithromycin and Proxalutamide under combination.
Lead Product(s): Dutasteride,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Corpometria Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 11, 2020
Details:
The clinical study is a randomized controlled study of an anti-androgen (5-alpha reductase inhibitor) as a treatment for mildly symptomatic COVID-19 patients. The companies have teamed but to evaluate efficacy and safety of Proxalutamide.
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Kintor Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2020
Details:
Breakthrough discovery by Applied Biology scientists paves way for a Generic Anti-androgen as a treatment for Covid-19.
Lead Product(s): Proxalutamide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corpometria Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
Details:
On the heels of discovering an association between covid-19 and androgens, applied biology to expand its research program into anti-androgen based therapies.
Lead Product(s): Cannabidiol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
Details:
Drug discovery platform to rapidly predict blocking of covid-19 pneumocyte cellular entry.
Lead Product(s): Androgens
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
